7.15
-0.18(-2.46%)
Currency In USD
| Previous Close | 7.33 |
| Open | 7.4 |
| Day High | 7.47 |
| Day Low | 7.15 |
| 52-Week High | 11.31 |
| 52-Week Low | 6.02 |
| Volume | 3.69M |
| Average Volume | 2.96M |
| Market Cap | 1.5B |
| PE | -39.72 |
| EPS | -0.18 |
| Moving Average 50 Days | 8.11 |
| Moving Average 200 Days | 8.5 |
| Change | -0.18 |
If you invested $1000 in BioCryst Pharmaceuticals, Inc. (BCRX) 10 years ago, it would be worth $579.89 as of October 05, 2025 at a share price of $7.15. Whereas If you bought $1000 worth of BioCryst Pharmaceuticals, Inc. (BCRX) shares 5 years ago, it would be worth $1,958.9 as of October 05, 2025 at a share price of $7.15.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioCryst Completes Sale of European ORLADEYO® (berotralstat) Business
GlobeNewswire Inc.
Oct 01, 2025 11:00 AM GMT
– Transaction valued at $250 million, with up to $14 million in future milestones – – BioCryst will focus on driving ORLADEYO sales in the U.S. while Neopharmed Gentili will lead commercialization across Europe – – Provides a significant and immediat
BioCryst Announces Departure of Dr. Helen Thackray
GlobeNewswire Inc.
Aug 11, 2025 11:00 AM GMT
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Dr. Helen Thackray, chief research and development officer, will leave the company September 1, 2025 and transition i
BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December
GlobeNewswire Inc.
Jul 31, 2025 11:00 AM GMT
RESEARCH TRIANGLE PARK, N.C., July 31, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its president and chief executive officer, Jon Stonehouse, has informed the board of directors of his intention to re